tiprankstipranks
Trending News
More News >
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market

Inhibikase Therapeutics (IKT) Cash flow

Compare
172 Followers

Inhibikase Therapeutics Cash Flow

IKT's free cash flow for Q3 2025 was $-10.59M. For the 2025 fiscal year, IKT's free cash flow was decreased by $-1.05M and operating cash flow was $-10.59M. See a summary of the company’s cash flow.
Cash Flow
Dec 24Dec 23Dec 22Dec 21Dec 20
Operating Cash Flow
$ -19.15M$ -18.09M$ -17.35M$ -14.30M$ -1.13M
Investing Cash Flow
$ -37.00M$ 11.66M$ -16.01M$ 0.00$ 0.00
Financing Cash Flow
$ 103.48M$ 8.41M$ -204.77K$ 41.09M$ 15.06M
End Cash Position
$ 56.49M$ 9.17M$ 7.19M$ 40.75M$ 13.95M
Free Cash Flow
$ -19.15M$ -18.10M$ -17.59M$ -14.30M$ -1.13M
Currency in USD

Inhibikase Therapeutics Cash Flow